PDGFRA Immunostaining Can Help in the Diagnosis of Gastrointestinal Stromal Tumors
Authors:
- Clara MillefantiCMClara Millefanti
- Elena ConcaECElena Conca
- Tiziana NegriTNTiziana Negri
- Cristina PiacenzaCPCristina Piacenza
- Marco A. PierottiMPMarco A. Pierotti
- Elena TamboriniETElena Tamborini
- Silvana PilottiSPSilvana Pilotti
- 1 May 2008
- journal article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 32 (5) , 738-743
Abstract
Gastrointestinal stromal tumors (GISTs) are characterized by the presence of activating mutations affecting the c-Kit or the PDGFRA gene. Although these mutations are mutually exclusive, their proteins are coexpressed in many GISTs with various modulations of immunostaining depending on which gene is mutated. CD117 expression is currently considered a sensitive (although not entirely specific) marker of KIT activation, but there is no consensus concerning the reliability of PDGFRA antibody. Our database contains 236 molecularly analyzed GISTs, and we here describe the 180 cases that underwent KIT/PDGFRA immunophenotyping. By correlating the immunophenotype with the molecular status of the genes expected to be involved, we observed the coexpression of KIT and PDGFRA in the majority of the mutated c-Kit and wild-type c-Kit/PDGFRA GISTs, whereas the -/+ immunophenotype (0% vs. 48.6%) and PDGFRA dotlike immunostaining (P<0.005) segregated with the PDGFRA-mutated GISTs. Taking either the dotlike decoration (26 cases) or -/+ immunophenotype (5 cases) as hallmarks of PDGFRA mutation, the presence of a PDGFRA mutation was predicted in 31 (83.8%) of the 37 PDGFRA mutated GISTs. Our findings suggest that, when critically applied, the routine use of CD117/PDGFRA immunophenotyping is a useful diagnostic tool (especially in CD117-negative cases) as it correctly predicts the presence of PDGFRA mutations in most cases.Keywords
This publication has 16 references indexed in Scilit:
- The role of KIT in the management of patients with gastrointestinal stromal tumorsHuman Pathology, 2007
- c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal TumorsClinical Cancer Research, 2007
- PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcomaThe Journal of Pathology, 2006
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- PDGFRα‐ and c‐kit‐mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical featuresHistopathology, 2005
- Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225Journal of Clinical Oncology, 2005
- Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumorsOncogene, 2004
- Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivityThe Journal of Pathology, 2004
- Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumorsGastroenterology, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003